• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity - Product Image

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

  • ID: 2358429
  • December 2012
  • 112 Pages
  • GBI Research

FEATURED COMPANIES

  • JCR Pharmaceuticals
  • Medipost
  • Pharmicell
  • Reliance Life Sciences
  • Stem Cell Technologies i
  • Stempeutics Research
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity”. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • JCR Pharmaceuticals
  • Medipost
  • Pharmicell
  • Reliance Life Sciences
  • Stem Cell Technologies i
  • Stempeutics Research
  • MORE

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction

3 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview
3.1 Introduction
3.2 Market Characterization and Forecasts - Overview
3.2.1 Revenue Forecasts
3.2.2 Cost of Therapy
3.2.3 Allogeneic and Autologous Share
3.2.4 Stem Cell Therapy Patient Pool
3.3 Drivers and Barriers
3.3.1 Drivers
3.3.2 Barriers

4 Stem Cell Therapy Market in Asia-Pacific to 2018 - India
4.1 Introduction
4.2 Regulatory Landscape
4.3 Market Characterization and Forecasts - Overview
4.3.1 Revenue Forecasts
4.3.2 Cost of Therapy
4.3.3 Stem Cell Patient Pool
4.4 CABG Market Characterization and Forecasts
4.4.1 Introduction
4.4.2 Revenue Forecasts
4.4.3 Cost of Therapy
4.4.4 Stem Cell Patient Pool
4.5 Type 2 DM Market Characterization and Forecasts
4.5.1 Introduction
4.5.2 Revenue Forecasts
4.5.3 Cost of Therapy
4.5.4 Stem Cell Patient Pool
4.6 LSCT Market Characterization and Forecasts
4.6.1 Introduction
4.6.2 Revenue Forecasts
4.6.3 Cost of Therapy
4.6.4 Stem Cell Patient Pool

5 Stem Cell Therapy Market in Asia-Pacific to 2018 - China
5.1 Introduction
5.2 Regulatory Landscape
5.3 Market Characterization and Forecasts - Overview
5.3.1 Type 1 DM Market Characterization and Forecasts

6 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan
6.1 Introduction
6.2 Regulatory Landscape
6.3 Steroid Refractory aGvHD Market Characterization and Forecasts
6.3.1 Overview
6.3.2 Revenue Forecasts
6.3.3 Cost of Therapy
6.3.4 Stem Cell Patient Pool

7 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore
7.1 Introduction
7.2 Regulatory Landscape
7.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002)
7.2.2 Human Tissue Research (November 2002)
7.2.3 Research Involving Human Subjects (November 2004)
7.2.4 Genetic Testing and Genetic Research (November 2005)
7.2.5 Personal Information in Biomedical Research (May 2007)
7.2.6 Donation of Human Eggs for Research (November 2008)
7.2.7 Human-Animal Combinations in Stem Cell Research (September 2010)

8 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea
8.1 Introduction
8.2 Regulatory Landscape
8.3 Market Characterization and Forecasts - Overview
8.3.1 Revenue Forecasts
8.3.2 Cost of Therapy
8.3.3 Stem Cell Patient Pool
8.4 Cupistem Market Characterization and Forecasts
8.4.1 Overview
8.4.2 Revenue Forecasts
8.4.3 Cost of Therapy
8.4.4 Stem Cell Patient Pool
8.5 HCG-AMI Market Characterization and Forecasts
8.5.1 Overview
8.5.2 Revenue Forecasts
8.5.3 Cost of Therapy
8.5.4 Stem Cell Patient Pool
8.6 Cartistem Market Characterization and Forecasts
8.6.1 Overview
8.6.2 Revenue Forecasts
8.6.3 Cost of Therapy
8.6.4 Stem Cell Patient Pool
8.7 CCG Market Characterization and Forecasts
8.7.1 Overview
8.7.2 Revenue Forecasts
8.7.3 Cost of Therapy
8.7.4 Stem Cell Patient Pool

9 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis
9.1 Pipeline Analysis by Phase
9.2 Pipeline Analysis by Sponsors/Collaborators
9.3 Pipeline Analysis by Country
9.3.1 India Stem Cell R&D Pipeline
9.3.2 China Stem Cell R&D Pipeline
9.3.3 Japan Stem Cell R&D Pipeline
9.3.4 Singapore Stem Cell R&D Pipeline
9.3.5 South Korea Stem Cell R&D Pipeline
9.3.6 Product Profiles of Promising Molecules
9.3.7 Product Profiles of Marketed Products

10 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape
10.1 Stempeutics Research
10.1.1 Overview
10.1.2 Product Pipeline
10.2 Reliance Life Sciences
10.2.1 Overview
10.2.2 Product Pipeline
10.3 International Stem Cell Services
10.3.1 Overview
10.3.2 Product Pipeline
10.4 Shenzhen Beike Biotechnology
10.4.1 Overview
10.4.2 Product Pipeline
10.5 JCR Pharmaceuticals
10.5.1 Overview
10.5.2 Product Pipeline
10.6 ES Cells International (Subsidiary of BioTime, Inc)
10.6.1 Overview
10.6.2 Product Pipeline
10.7 Stem Cell Technologies i
10.7.1 Overview
10.7.2 Product Pipeline
10.8 Pharmicell
10.8.1 Overview
10.8.2 Product Pipeline
10.9 Medipost
10.9.1 Overview
10.9.2 Product Pipeline

11 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations
11.1 Overview
11.2 M&A Deals
11.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011
11.2.2 BioTime Acquired ES Cell International - May 3, 2010
11.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007
11.3 Licensing Deals
11.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011
11.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011
11.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010
11.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010
11.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009
11.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008
11.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007
11.4 Co-Development Deals
11.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011
11.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009
11.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008
11.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007

12 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Bibliography
12.4 Research Methodology
12.4.1 Coverage
12.4.2 Secondary Research
12.4.3 Primary Research
12.5 Therapeutic Landscape
12.5.2 Market Size by Geography
12.6 Geographical Landscape
12.7 Pipeline Analysis
12.8 Competitive Landscape
12.8.1 Expert Panel Validation
12.9 Contact Us
12.10 Disclaimer

1.1 List of Tables

Table 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018
Table 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (‘000), 2012-2018
Table 3: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018
Table 4: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (‘000), 2012-2018
Table 5: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($’000), 2012-2018
Table 6: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018
Table 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018
Table 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018
Table 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018
Table 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (‘000), 2012-2018
Table 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($’000), 2012-2018
Table 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018
Table 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018
Table 14: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018
Table 15: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018
Table 16: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (‘000), 2012-2018
Table 17: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018
Table 18: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018
Table 19: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018
Table 20: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018
Table 21: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018
Table 22: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018
Table 23: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018
Table 24: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018
Table 25: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018
Table 26: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018
Table 27: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts, 2012-2018
Table 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018
Table 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018
Table 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018
Table 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018
Table 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018
Table 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018
Table 34: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase, 2012
Table 35: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators, 2012
Table 36: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country, 2012
Table 37: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase, 2012
Table 38: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II/III Pipeline Analysis, 2012
Table 39: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II Pipeline Analysis, 2012
Table 40: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase I/II Pipeline Analysis, 2012
Table 41: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Unknown Phase, 2012
Table 42: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase, 2012
Table 43: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Post-Market Pipeline Analysis, 2012
Table 44: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase II Pipeline Analysis, 2012
Table 45: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I/II Pipeline Analysis, 2012
Table 46: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I Pipeline Analysis, 2012
Table 47: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Clinical Pre-Test Pipeline Analysis, 2012
Table 48: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Unknown Phase, 2012
Table 49: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase, 2012
Table 50: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase III Stage Molecules Pipeline Analysis, 2012
Table 51: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II/III Stage Molecules Pipeline Analysis, 2012
Table 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II Stage Molecules Pipeline Analysis, 2012
Table 53: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I/II Stage Molecules Pipeline Analysis, 2012
Table 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I Stage Molecules Pipeline Analysis, 2012
Table 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Singapore, Phase I/II Stage Molecules Pipeline Analysis, 2012
Table 56: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase, 2012
Table 57: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase III Molecules Pipeline Analysis, 2012
Table 58: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II/III Molecules Pipeline Analysis, 2012
Table 59: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II Molecules Pipeline Analysis, 2012
Table 60: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I/II Molecules Pipeline Analysis, 2012
Table 61: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I Molecules Pipeline Analysis, 2012
Table 62: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Unknown Phase, 2012
Table 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, R&D Pipeline, 2012
Table 64: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, R&D Pipeline, 2012
Table 65: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services Limited, R&D Pipeline, 2012
Table 66: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology R&D Pipeline, 2012
Table 67: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Co. Ltd, R&D Pipeline, 2012
Table 68: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell, R&D Pipeline, 2012
Table 69: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, R&D Pipeline, 2012
Table 70: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview, 2007-2012

1.2 List of Figures

Figure 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Overview, 2012
Figure 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018
Figure 3: Stem Cell Therapy Market in Asia-Pacific to 2018, Cost of Therapy Overview ($), 2012
Figure 4: Stem Cell Therapy Market in Asia-Pacific to 2018, Allogeneic vs. Autologous (%), 2012
Figure 5: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (‘000), 2012-2018
Figure 6: Stem Cell Therapy Market in Asia-Pacific to 2018, Drivers and Barriers, 2012
Figure 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018
Figure 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Cost of Therapy Overview ($), 2012
Figure 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (‘000), 2012-2018
Figure 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($’000), 2012-2018
Figure 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018
Figure 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018
Figure 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018
Figure 14: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018
Figure 15: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (‘000), 2012-2018
Figure 16: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($’000), 2012-2018
Figure 17: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018
Figure 18: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018
Figure 19: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Regulatory Framework Timeline, 1998-2009
Figure 20: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018
Figure 21: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018
Figure 22: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (‘000), 2012-2018
Figure 23: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, MHLW Stem Cell Guidelines, 2010
Figure 24: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, JR-031 Overview, 2012
Figure 25: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018
Figure 26: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018
Figure 27: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018
Figure 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Stem Cell Therapeutics Approval Process, 2011
Figure 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Biopharmaceutical Implementation Strategies, 2011
Figure 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018
Figure 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Autologous and Allogeneic Share (%), 2012
Figure 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Marketed Products Share (%), 2012 and 2018
Figure 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cost of Therapy ($), Overview, 2012
Figure 34: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018
Figure 35: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018
Figure 36: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018
Figure 37: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018
Figure 38: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018
Figure 39: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018
Figure 40: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts (Absolute), 2012-2018
Figure 41: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018
Figure 42: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018
Figure 43: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018
Figure 44: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018
Figure 45: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018
Figure 46: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018
Figure 47: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase (%), 2012
Figure 48: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators (%), 2012
Figure 49: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country (%), 2012
Figure 50: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase (%), 2012
Figure 51: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase (%), 2012
Figure 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase (%), 2012
Figure 53: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase (%), 2012
Figure 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, Overview, 2012
Figure 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, Overview, 2012
Figure 56: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services, Overview, 2012
Figure 57: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology Overview, 2012
Figure 58: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Overview, 2012
Figure 59: Stem Cell Therapy Market in Asia-Pacific to 2018, ES Cells International, Overview, 2012
Figure 60: Stem Cell Therapy Market in Asia-Pacific to 2018, Stem Cell Technologies i, Overview, 2012
Figure 61: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell Overview, 2012
Figure 62: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, Overview, 2012
Figure 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview (%), 2007-2012
Figure 64: GBI Research Market Forecasting Model

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • JCR Pharmaceuticals
  • Medipost
  • Pharmicell
  • Reliance Life Sciences
  • Stem Cell Technologies i
  • Stempeutics Research
  • MORE

Stem Cell Research in Asia-Pacific a “Growth Engine” for Region’s Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries’ Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a “new growth engine” for the nation’s economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn’s disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research’s analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate – however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals’ JR-031 in Japan in 2014, and FCB Pharmicell’s Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Note: Product cover images may vary from those shown

- Stempeutics Research
- Reliance Life Sciences
- International Stem Cell Services
- Shenzhen Beike Biotechnology
- JCR Pharmaceuticals
- ES Cells International (Subsidiary of BioTime, Inc)
- Stem Cell Technologies i
- Pharmicell
- Medipost

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos